Telangana Aims to Establish Hyderabad as a Global Drug Discovery Hub
Advertisement
The proposed plan is being developed with industry stakeholders and technology organizations, including Nasscom.
Telangana has taken a significant step toward positioning Hyderabad as a global drug discovery destination by planning an integrated ecosystem that supports the development of new medicines from research through commercialization.
The initiative has focused on strengthening innovation capabilities while leveraging the city's long-standing pharmaceutical expertise to attract researchers, startups, investors, and global life sciences companies.
Hyderabad has long been recognized as one of India's most important pharmaceutical clusters. Often referred to as the country's "Genome Valley," the region is home to major pharmaceutical manufacturers, biotechnology companies, contract research organizations, and academic institutions.
The city contributes nearly one-third of global vaccine production and plays a critical role in the manufacturing of generic medicines and active pharmaceutical ingredients (APIs) supplied to international markets. This manufacturing strength has made Hyderabad a key player in the global healthcare supply chain.
The Telangana government is now seeking to move the state higher up the pharmaceutical value chain by encouraging drug discovery and innovation.
The proposed plan is being developed with industry stakeholders and technology organizations, including Nasscom.
The ecosystem is expected to bring together Indian and international pharmaceutical companies, global capability centres (GCCs), research institutions, startups, and venture capital investors to support the entire drug development lifecycle.
"We are creating the conditions for the next generation of therapies to be discovered, developed and delivered from Telangana," IT and Industries Minister D Sridhar Babu said.
The initiative also aims to strengthen Hyderabad's capabilities in emerging areas such as cell and gene therapies, precision medicine, biologics, and other advanced treatment platforms.
Shared research infrastructure, funding opportunities for early-stage innovators, and stronger collaboration between academia and industry are expected to help accelerate scientific discoveries into commercially viable products.
Stay tuned for more such updates on Digital Health News
